I

Immuneering Corp
NASDAQ:IMRX

Watchlist Manager
Immuneering Corp
NASDAQ:IMRX
Watchlist
Price: 2.1 USD -0.47% Market Closed
Market Cap: 62.3m USD
Have any thoughts about
Immuneering Corp?
Write Note

Immuneering Corp
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Immuneering Corp
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
I
Immuneering Corp
NASDAQ:IMRX
Other Liabilities
$4.2m
CAGR 3-Years
103%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Liabilities
$33B
CAGR 3-Years
4%
CAGR 5-Years
16%
CAGR 10-Years
28%
Gilead Sciences Inc
NASDAQ:GILD
Other Liabilities
$24.4B
CAGR 3-Years
63%
CAGR 5-Years
29%
CAGR 10-Years
39%
Amgen Inc
NASDAQ:AMGN
Other Liabilities
$4.5B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Liabilities
$2.5B
CAGR 3-Years
56%
CAGR 5-Years
50%
CAGR 10-Years
44%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Liabilities
$1.8B
CAGR 3-Years
35%
CAGR 5-Years
13%
CAGR 10-Years
23%
No Stocks Found

Immuneering Corp
Glance View

Market Cap
61.5m USD
Industry
Biotechnology

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. The company is headquartered in Cambridge, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-07-30. The firm is focused on improving patient outcomes by advancing a pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Its development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Its lead product candidate, IMM-1-104, is designed to be a selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. The firm's oncology programs target mutations of the RAS/RAF/MEK/ERK, (MAPK) and the PI3K/AKT/mTOR (mTOR), pathways. Its oncology programs include Dual-MEK: IMM-1-104, MEK-io, Trifecta-MEK, KRAS4B, RAS Induction, Covalent-MEK, and PI3K-alpha. The firm's neuroscience pipeline on Alzheimer's Disease (AD). Its neuroscience programs include IMM-ALL-01 and IMM-ALL-03.

IMRX Intrinsic Value
2.89 USD
Undervaluation 27%
Intrinsic Value
Price
I

See Also

What is Immuneering Corp's Other Liabilities?
Other Liabilities
4.2m USD

Based on the financial report for Dec 31, 2023, Immuneering Corp's Other Liabilities amounts to 4.2m USD.

What is Immuneering Corp's Other Liabilities growth rate?
Other Liabilities CAGR 3Y
103%

Over the last year, the Other Liabilities growth was -7%. The average annual Other Liabilities growth rates for Immuneering Corp have been 103% over the past three years .

Back to Top